Project Grant F31CA294844
- This Project Grant, awarded by the National Science Foundation's Biological Sciences program (CFDA 47.074), provides $900,000 in funding to The Regents of the University of Colorado from February 1, 2025 to January 31, 2028. The project focuses on uncovering the molecular mechanisms by which the DNA methyltransferase 1 (DNMT1) enzyme regulates gene silencing and the inheritance of distinct cell identities. The research will utilize structural biology, biochemistry, and cell biology methods to...
- This $462,000 Project Grant award from the National Institute of General Medical Sciences (NIGMS), under the Biomedical Research and Research Training program (CFDA 93.859), supports research to establish the epigenetic mechanisms that govern embryonic stem cell (ESC) biology. The research aims to define how ESC gene expression programs and biology are regulated by DNA methylation and the TET family of DNA demethylases. Key objectives include: Dissecting the molecular and biological requirements...
- This Project Grant award from the National Institute of Mental Health (NIMH) under the Mental Health Research Grants program (CFDA 93.242) provides $609,386 to The University of Texas Southwestern Medical Center (UT Southwestern) to elucidate the role of DNMT3A phosphorylation in regulating DNA methylation and its impact on neural gene expression and animal behavior. The 5-year project aims to: 1) determine how DNMT3A phosphorylation affects its methyltransferase function, 2) define the role...
- The U.S. Department of Health and Human Services, National Institutes of Health (NIH) Office of the Director awarded a $539,250 Project Grant under the NIH Research Infrastructure Programs (CFDA 93.351) to Baylor College of Medicine. The grant, awarded from April 1, 2025 to March 31, 2027, supports the development of mouse models with an inducible CRISPR/Cas9 system for targeted manipulation of DNA methylation. The goal is to create simple, robust tools for locus-specific editing of DNA...
- This federal Project Grant award of $135,206 from the National Human Genome Research Institute (NHGRI), under the Human Genome Research Federal Grant Program (CFDA 93.172), supports the development of two novel single-cell functional genomic technologies to investigate the causal relationship between DNA methylation changes and gene expression in human diseases. The award recipient, The Regents of the University of California, San Francisco (UCSF), aims to: 1) Develop a single-cell version of...
- This $693,942 National Institutes of Health National Heart Lung and Blood Institute Project Grant funds research at Northwestern University aimed at elucidating epigenetic modifiers of regulatory T cell function following viral pneumonia. The goal is to establish causal links between DNA methyltransferase activity, the DNMT adapter UHRF1, and DNA hypermethylation signatures in regulatory T cells during aging and their impaired reparative function after severe viral pneumonia. Through three...
- This Project Grant award of $950,000.00 from the National Science Foundation's Biological Sciences (CFDA 47.074) program supports research to investigate how the enzyme thymine DNA glycosylase (TDG) is regulated and targeted throughout the genome to maintain proper DNA methylation patterns. The research aims to improve understanding of how DNA methylation landscapes are established and maintained under both normal and disease conditions, which could lead to future clinical applications. The...
- This Project Grant award from the National Institute of Environmental Health Sciences (NIEHS), under the Environmental Health federal grant program (CFDA 93.113), provides $127,384 to the University of Pittsburgh to research the dynamics of oxidative DNA demethylation and the impact of chromatin on this process. The key objectives of the research are to: 1) determine the dynamics of the enzyme thymine DNA glycosylase (TDG) as it diffuses and binds to chromatin in living cells, and its binding to...
- This $462,454 Project Grant award, provided by the Department of Health and Human Services National Institutes of Health (NIH) under the Trans-NIH Research Support program (CFDA 93.310), aims to characterize DNA methylation dynamics in trisomy 21-associated hematopoiesis and leukemia. The project, awarded to the Icahn School of Medicine at Mount Sinai, will employ the institution's innovative single-cell multi-omic sequencing technology, SHARE-ME-SEQ, to map DNA methylation, chromatin...
- This National Science Foundation Project Grant award of $292,630 provides funding for "MOLECULAR DISSECTION OF ARABIDOPSIS DNA METHYLATION MECHANISM" research being conducted at the University of Missouri-St. Louis from August 15, 2022 through November 30, 2022. The research aims to further the understanding of how DNA methyltransferase enzymes locate specific sites for methylation modification in complex genomes like plants and mammals. This has implications for genome integrity and...
MECHANISMS OF DNA METHYLATION AND ITS REGULATION BY EPIGENETIC HISTONE MODIFICATIONS - PROJECT SUMMARY A HALLMARK IN CANCER IS GENOME-WIDE HYPOMETHYLATION AND PROMOTER SPECIFIC HYPERMETHYLATION. A GENOME- WIDE REDUCTION IN DNA METHYLATION IS ALSO OBSERVED IN AGEING, LINKING INCREASED RISK FOR CANCER AND DEMENTIA WITH AGE. THIS MAY BECOME INCREASINGLY PREVALENT SINCE THE GLOBAL POPULATION IS AGING AND LIFE EXPECTANCIES ARE RISING. THUS, MANAGING AND MONITORING DNA METHYLATIONS HAS BECOME A PRIORITY FOR SCIENTISTS AND CLINICIANS. CURRENT MANAGING STRATEGIES OFTEN TARGET THE CHROMATIN MODIFIERS THAT ESTABLISH AND MAINTAIN DNA METHYLATION. CENTRAL TO MAINTAINING DNA METHYLATION IN MAMMALS IS THE DNA METHYLTRANSFERASE 1 (DNMT1), WHICH IS OVEREXPRESSION IN A RANGE OF CANCERS SUCH AS GASTRIC, PANCREATIC, COLORECTAL, AND LUNG CANCER. HOWEVER, CLINICAL STRATEGIES TO SPECIFICALLY INHIBIT DNMT1 ARE LIMITED. THE MOST COMMON FDA-APPROVED INHIBITOR LACKS SPECIFICITY, LEADING TO UNDESIRABLE OFF-TARGET EFFECTS. IT'S DESIRABLE TO HAVE SPECIFIC INHIBITORS AGAINST DNMT1. HOWEVER, DEVELOPING THESE INHIBITORS MAY HALT FROM MISSING MECHANISTIC KNOWLEDGE ON DNMT1 METHYLATION. SPECIFICALLY, WE ARE MISSING EXPLANATIONS FOR DNMT1'S SELECTIVITY AND REGULATION BY CHROMATIN MODIFICATION. I HYPOTHESIZE THE MOLECULAR INTERACTIONS BETWEEN DNMT1 AND CHROMATIN EXPLAINS THIS MISSING MECHANISTIC INFORMATION. AIM 1 OF MY PROPOSED RESEARCH IS TO DETERMINING THE CRYO-EM STRUCTURE OF DNMT1 WITH SPECIFICALLY MODIFIED NUCLEOSOMES, REVEALING INSIGHTS INTO THESE MECHANISMS. THIS WILL BE FOLLOWED BY THOROUGH VALIDATION THROUGH IN VITRO AND IN VIVO EXPERIMENTS. ANOTHER STRATEGY FOR MANAGING DNA METHYLATION IS BY TARGETING THE ENZYMES REGULATING DNMT1. A SIGNIFICANT HISTONE POSTTRANSLATIONAL MODIFICATION REGULATING DNMT1, MONO-UBIQUITINATED H3 (H3UB), CURRENTLY HAS NO IDENTIFIED DEUBIQUITINATING ENZYME. OUR RESEARCH HAS IDENTIFIED A DEUBIQUITINASE THAT CAN REMOVE H3UB IN VITRO, AND PRELIMINARY STRUCTURAL STUDIES REVEALED THAT IT EXHIBITS A UNIQUE MECHANISM. AIM 2 OF MY PROPOSED RESEARCH INVOLVES CHARACTERIZING THIS H3UB DEUBIQUITINASE IN CELLS, UNDERSTANDING HOW IT REGULATES DNA METHYLATION, AND RESOLVING THE DEUBIQUITINATION MECHANISM USING CRYO-EM. IN SUMMARY, MY RESEARCH FOCUSES ON UNCOVERING THE MECHANISMS OF DNA METHYLATION AND IT REGULATION, AIMING TO OPEN THERAPEUTIC AVENUES FOR AGE-RELATED DISEASES AND CANCER.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $0 | 5/28/25 | ||
| Not listed | $564 | 5/28/25 | ||
| Not listed | $564 | 5/28/25 | ||
| Not listed | $49.0k | 5/7/25 | ||
| Not listed | $49.0k | 5/7/25 |